A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. (Q50551357)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 August 2012

Language	Label	Description	Also known as
English	A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.	scientific article published on 16 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Kuo-Chin Chang

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Chao-Hung Hung

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Sheng-Nan Lu

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Jing-Houng Wang

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Chuan-Mo Lee

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Chien-Hung Chen

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Ming-Fang Yen

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Sheng-Chieh Lin

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Yi-Hao Yen

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Ming-Chao Tsai

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Po-Lin Tseng

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Tsung-Hui Hu

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

language of work or name

0 references

publication date

16 August 2012

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

67

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

2766-2772

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

The natural history of hepatitis C virus (HCV) infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Long-term follow-up study of sustained biochemical responders with interferon therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Prevention of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS269

21 January 2018

Identifiers

10.1093/JAC/DKS269

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/22899800

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50551357&oldid=1590463190"